Skip to main content
Premium Trial:

Request an Annual Quote

Gentel Biosciences Closes Shop; Assets Purchased by Intuitive Biosciences

NEW YORK (GenomeWeb News) – Intuitive Biosciences today announced an agreement to purchase the animal health and research tools assets and businesses of Gentel Biosciences for an undisclosed amount.

The deal is expected to close during the second quarter.

Gentel has been out of business since March 1, according to its website.

Intuitive is based in Madison, Wis., and as part of the acquisition it bought "all of [Gentel's] intellectual property … and substantially all of [its] assets," as well as licensing agreements that Gentel had, Shawn Guse, President and CEO of Intuitive told GenomeWeb Daily News.

Intuitive also is offering its own proprietary content and finishing development work on three proprietary tests for non-human health primate health. Two are pathogen-free panels, and one is a tuberculosis test that will appear on the first two panels, as well as a stand-alone test.

The TB panel, Guse said, will also be adapted to other animal species.

In addition to its assays, Intuitive is working on "systematizing our biomarker development platform," and is talking with potential partners about using their high-throughput screening and bioinformatics platform, he said. Guse declined further comment.

As part of the purchase, Intuitive retained Gentel's scientific staff and now has six employees.

Guse's background is as a securities lawyer and he previously was general counsel at TomoTherapy. He eventually became its vice president of international operations, then became CEO of its spinout firm called Compact Particle Acceleration.

Gentel, which also had been based in Madison, was primarily a protein microarray firm and was spun out of the University of Wisconsin, Madison in 2000. Former officials from the firm declined to comment or did not respond to requests for comment.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.